Zymeworks is pleased to announce the acceptance of an abstract for poster presentation featuring preclinical data on ZW1528, a novel IL-4R⍺ x IL-33 bispecific molecule, at the upcoming American Thoracic Society (ATS) Annual Meeting being held May 18-21, 2025 in San Francisco, CA.
“We are excited to share preclinical updates on ZW1528, a differentiated bispecific molecule that represents a novel approach to addressing respiratory inflammation at ATS this year,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “Our expansion into underscores our commitment to developing innovative therapeutic approaches that have the potential to improve outcomes for patients with currently limited treatment options.”
Poster Presentation Details
Title: ZW1528, A Bispecific Antibody Targeting IL-4Ra And IL-33, Potently Inhibits Key Mediators Of Airway Inflammation
Abstract: 12571
Session Category: B33 – WHEEZING THROUGH THE MECHANISMS: UNPACKING ASTHMA’S SECRETS
Session Title: Thematic Poster Session
Poster Board: P1567
Date and Time: May 19 at 11:30 am – 1:15 pm PT
The poster will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications after the time of presentation at the conference.
About ZW1528
ZW1528 is a novel IL-4R⍺ x IL-33 bispecific molecule designed to address respiratory inflammation such as mixed-type chronic obstructive pulmonary disease (“COPD”) by inhibiting multiple pathways. By blocking three cytokines (IL-4, IL-13 and IL-33) in a single biologic, ZW1528 offers a unique approach to inhibit clinically validated pathways. The bispecific antibody is designed to provide complete, prolonged IL4R⍺ blockade with simultaneous blockade of IL-33. Based on non-clinical in vitro studies, the bispecific can independently suppress IL-13, IL-4 and IL-33 driven cell signaling equivalent to that achieved with anti-IL-4R⍺ monoclonal antibody (“mAb”) or anti-IL-33 clinical benchmarks mAbs. Furthermore, in preclinical studies, ZW1528-mediated blockade of cytokine-driven activation of human epithelial cells was superior to that achieved with mAbs targeting either IL-4R⍺ or IL-33, indicating potential benefits of dual blockade. Additionally, preclinical studies with human peripheral blood mononuclear cells (“PBMCs”) demonstrate ZW1528 provides blockade of IL-33 mediated effects beyond that achievable with an anti-IL33 benchmark mAb. With native Immunoglobulin G (“IgG”)-like geometry, ZW1528 demonstrates the potential for high manufacturability and incorporates half-life extending Fc modifications.
Additional information on ZW1528 and the company’s other autoimmune and inflammatory programs is available in the December 12, 2024 R&D Day Presentation.
